Post by Alnylam Pharmaceuticals

290,528 followers

There is a tremendous unmet need for patients with bleeding disorders, as most conditions have no approved treatment options. Hear from Alnylam Program Leader John Gansner on how ALN-6400 could potentially change that, and watch the replay from yesterday’s RNAi Roundtable: https://bit.ly/4oHlMbT #RNAiTherapeutics #BleedingDisorders

Post content

Video Content